{"id":3116,"date":"2026-07-20T06:51:40","date_gmt":"2026-07-20T06:51:40","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=3116"},"modified":"2026-07-20T06:51:42","modified_gmt":"2026-07-20T06:51:42","slug":"biotech-theolytics-relocates-to-arc-oxford","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/","title":{"rendered":"Biotech Theolytics Relocates to ARC Oxford"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_8354c0313ccff63113f9d7f250680304\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg 1920w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-300x200.jpeg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1024x682.jpeg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-768x512.jpeg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1000x666.jpeg 1000w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Biotech Theolytics Relocates to ARC Oxford<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus. The company joins a thriving community of more than 30 science and technology organisations at ARC Oxford, including <a href=\"https:\/\/www.omass.com\/\">OMass Therapeutics<\/a>, <a href=\"https:\/\/www.fluorok.com\/\">FluoRok<\/a>, <a href=\"https:\/\/www.seloxium.com\/\">Seloxium<\/a> and <a href=\"https:\/\/perspectum.com\/\">Perspectum<\/a>, further strengthening the campus\u2019 position as a hub for cutting-edge innovation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Founded in 2017 as a spinout from the University of Oxford, <a href=\"https:\/\/www.theolytics.com\/\">Theolytics<\/a> is working to develop best-in-class oncolytic immunotherapies for complex and difficult-to-treat solid tumours. Leveraging its proprietary Adenovo\u2122 platform, the company has pioneered a new approach to develop efficacious, targeted adenoviral candidates suitable for direct and intravenous delivery targeting stroma-rich tumours, a feature of major cancers, including ovarian, colorectal cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Theolytics\u2019 lead candidate THEO-260 has demonstrated its effectiveness against such tumours by killing cancer cells and cancer-associated fibroblasts that make up the stroma (or tumour microenvironment), while inducing tumour-targeted immune activation, in advanced preclinical models, including extensive panels of ovarian cancer patient samples. THEO-260 is being evaluated in two clinical trials in patients with advanced ovarian cancer: by intravenous (IV) delivery (OCTOPOD-IV) in the UK, Spain and Canada (NCT06618235); and by intraperitoneal (IP) delivery (OCTOPOD-IP) at The University of Texas MD Anderson Cancer Center in the US (NCT07211659).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Theolytics recently secured \u20ac8 million in funding from Horizon Europe 2025, the European Union\u2019s flagship research and innovation funding programme, to advance its planned Phase 2 study of THEO-260 in ovarian cancer, marking a significant step forward in its clinical development pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dan Williams, Director of Asset Management at ARC Oxford, said: \u201cWe\u2019re delighted to welcome Theolytics to ARC Oxford. Their pioneering work in oncolytic immunotherapy represents the kind of high-impact, translational science our campuses are designed to support. This partnership demonstrates how our fully fitted laboratory buildings can support such advanced research and development facilities and we look forward to watching the Theolytics business grow on our campus at ARC Oxford.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">David Apelian, CEO of Theolytics, added: \u201cRelocating to ARC Oxford marks an exciting new chapter for Theolytics. We join a vibrant community of innovators in an environment that champions collaboration, inclusivity, and growth, supporting our mission to develop life-changing therapies for cancer patients. The new facility will be a central hub from which to drive the development of our lead oncolytic immunotherapy THEO-260, which is advancing in two clinical trials in advanced ovarian cancer, with sites in the US, UK, Spain and Canada. It provides the space to grow the company and an excellent scientific base to enhance our platform and generate exciting new immunotherapy candidates against other solid tumours.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As an ARC Oxford member, Theolytics will have access to a curated programme of campus events, from networking and in-depth talks to exercise classes and socials, alongside seminar and co-working spaces. ARC Oxford was recently named Responsible Employer of the Year at the Oxpropfest Awards, and Workspace of the Year at the Hustle Awards recognising the campus\u2019 strong focus on customer service, inclusivity and commitment to reimagining how science and real estate intersect to foster collaboration, growth, and success for its member organisations.<\/p>\n\n\n    <section class=\"news-archive \" id=\"block_ba4a7968d9e9143588298422a6e0ddf0\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-300x213.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1024x728.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-768x546.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1000x711.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tARC Launches Adapt by ARC at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/06\/09\/fluorok-secures-funding\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349.jpg 1536w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-300x130.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-1024x444.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-768x333.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349-1000x434.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/Fluorok-founders-1536x1024-1-e1781003137349.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/06\/09\/fluorok-secures-funding\/\" target=\"_self\">\n\t\t\t\tFluoRok secures \u00a31.2M in funding strengthening the commercial proposition for the\u00a0 novel HF-free process for producing Fluorochemicals\u00a0\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus. The company joins a thriving community of more than 30 science and technology organisations at ARC Oxford, including OMass Therapeutics, FluoRok, Seloxium and Perspectum, further strengthening the campus\u2019 position as a hub for [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22,30],"tags":[4276,6210],"class_list":["post-3116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-corporate","tag-science-and-innovation","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biotech Theolytics Relocated to ARC Oxford<\/title>\n<meta name=\"description\" content=\"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech Theolytics Relocated to ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:51:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T06:51:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1279\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\"},\"headline\":\"Biotech Theolytics Relocates to ARC Oxford\",\"datePublished\":\"2026-07-20T06:51:40+00:00\",\"dateModified\":\"2026-07-20T06:51:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\",\"keywords\":[\"Science and innovation\",\"Life science and Health\"],\"articleSection\":[\"News\",\"Corporate\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\",\"name\":\"Biotech Theolytics Relocated to ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\",\"datePublished\":\"2026-07-20T06:51:40+00:00\",\"dateModified\":\"2026-07-20T06:51:42+00:00\",\"description\":\"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\",\"width\":1920,\"height\":1279},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotech Theolytics Relocates to ARC Oxford\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech Theolytics Relocated to ARC Oxford","description":"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/","og_locale":"en_US","og_type":"article","og_title":"Biotech Theolytics Relocated to ARC Oxford","og_description":"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/","og_site_name":"ARC Oxford","article_published_time":"2026-07-20T06:51:40+00:00","article_modified_time":"2026-07-20T06:51:42+00:00","og_image":[{"width":1920,"height":1279,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg","type":"image\/jpeg"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57"},"headline":"Biotech Theolytics Relocates to ARC Oxford","datePublished":"2026-07-20T06:51:40+00:00","dateModified":"2026-07-20T06:51:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg","keywords":["Science and innovation","Life science and Health"],"articleSection":["News","Corporate"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/","name":"Biotech Theolytics Relocated to ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg","datePublished":"2026-07-20T06:51:40+00:00","dateModified":"2026-07-20T06:51:42+00:00","description":"Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has relocated to ARC Oxford.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg","width":1920,"height":1279},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Biotech Theolytics Relocates to ARC Oxford"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=3116"}],"version-history":[{"count":1,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3116\/revisions"}],"predecessor-version":[{"id":3118,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3116\/revisions\/3118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/3117"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=3116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=3116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=3116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}